Menopause

A recap of the top-performing, most-viewed Contemporary OB/GYN stories from June 2026, including new SMFM guidance on acetaminophen in pregnancy, ACOG's break from federal vaccine recommendations, and our coverage of SLEEP 2026 in Baltimore.

A recap of the top FDA news stories covered by Contemporary OB/GYN in Q2 2026, spanning cervical cancer screening, menopause therapeutics, and antibiotic treatment for urinary tract infections.

A look ahead to the second half of 2026 for ob-gyns, including Viatris's pending FDA decision on a low-dose estrogen contraceptive patch and previews of the IDSOG, AUGS PFD Week, and The Menopause Society annual meetings.

Fiona C. Baker, PhD, explains how menopausal sleep disturbance differs from other forms of sleep disruption, citing the role of vasomotor symptoms, hormone changes, and an increased postmenopausal risk of sleep apnea in driving nighttime awakenings.

Among SWAN participants, sleep disturbance was independently associated with lower HRQoL relating to role-physical, role-emotional, and energy/fatigue, with no change in these associations over time.

In part 2 of our discussion with Fiona Baker, PhD, she details how to interpret data from the NIRVANA study, which revealed reductions in wakefulness after sleep onset in the elinzanetant group vs placebo.

Elinzanetant produced a numerically greater reduction in PSG-measured WASO vs placebo across the 12-week NIRVANA trial, with the effect more pronounced at week 4 than week 12.

A post hoc analysis of the phase 2 NIRVANA trial presented at SLEEP 2026 found that elinzanetant reduced WASO versus placebo across in-lab PSG, home-based Sleepiz One+ monitoring, and patient-reported Sleep Diary.

The total treatment effect of elinzanetant on sleep disturbance relative to placebo was -4.92 (95% CI, -5.73 to -4.12), indicating a clinically meaningful reduction.

Genevieve Neal-Perry, MD, PhD, highlights that phase 4 real-world data confirm that fezolinetant significantly reduces VMS bother, particularly in high-burden groups such as Black women and patients with obesity.

David Shalowitz explains why experts now recommend a dual approach for most patients with postmenopausal bleeding due to limitations in ultrasound accuracy.

At ACOG, David Shalowitz, MD, highlighted the biggest takeaways from April's updated guidance on postmenopausal bleeding.

Meaningful improvements in gynecologic care for LGBTQ patients require both environmental changes—inclusive waiting rooms, trained front desk staff, flexible scheduling—and clinical recalibration, including routine screening for contraceptive needs and menopausal symptoms regardless of gender identity or presentation.

Pelin Batur, MD, emphasizes that half of patients are unsatisfied with their sexual health and clinicians should normalize these concerns through simple, open-ended questions.

Jill Liss, MD, MSCP, FACOG, outlines aspects of hormonal and non-hormonal treatments for vasomotor symptoms.

In this discussion from ACOG's 75th Annual Meeting, Genevieve Neal-Perry, MD, PhD, explains how elinzanetant has impacted patients since it's approval in October 2025.

A study of 1206 women found that while many remain sexually active as they age, a higher number of menopausal symptoms was linked to decreased sexual satisfaction.

Contemporary OB/GYN will be on site in Washington, D.C. to cover the latest data out of the 75th Annual ACOG Clinical & Scientific Meeting.

The letter from the federal agency allows further phase 2 development for refisolone under an investigational new drug application.

ACOG now recommends a combination of transvaginal ultrasonography and endometrial tissue sampling for the initial evaluation of most patients presenting with postmenopausal bleeding.

According to ACOG, approximately 90% of patients diagnosed with endometrial cancer have postmenopausal bleeding. Read more on the College's updated recommendations below.

According to Amy Sarma, MD, moving beyond episodic office visits to multimodality care strategies is essential for reducing adverse cardiovascular outcomes in high-risk patients.

"These recommendations underscore the important and nuanced role of BMI in women’s health," write the authors.

In this video from the 2026 American College of Cardiology Annual Scientific Session & Expo, Amy Sarma, MD, details associations of cardiovascular disease and menopause.